Pole Sante Republique

Running trials

• Not yet recruiting

  Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer

  2026-526319-12-00· Phase 3· Source

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· Source

• Recruiting

  A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

  NCT07205822· Phase 3· Source

• Recruiting

  Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

  NCT06680596· Phase 2· Source

• Recruiting

  Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

  NCT06450314· Phase 2· Source

• Recruiting

  Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

  NCT06078384· Phase 2· Source

• Active, not recruiting

  A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 mutation

  NCT04964934· Phase 3· Source

• Completed

  PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

  NCT03079011· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer5 recruiting
• Triple-negative breast cancer2 recruiting

Researchers

No researcher is linked here yet.